The biggest change to the medical and pharmaceutical industry across Europe, the implementation of the Falsified Medicines Directive (FMD), came in to force in February 2019. So, six months later, what is the status of the directive across and what are the next steps for success? Oliver Pittock, managing director at pharmaceutical packaging expert, Valley Northern, explains.
Pharmacist
The FMD is a legal framework that was introduced by the European Union to improve the protection of the public against counterfeit, falsified and tampered medicines.
The directive orders that the more than 2,200 pharmaceutical companies that hold marketing authorisations to supply prescription medication to countries across the European Economic Area, must upload unique identifier codes for each pack of medicine manufactured or repackaged.